BSE has informed trading members that Indrayani Biotech Ltd (Scrip Code: 526445) has fixed a record date of April 28, 2026 for the purpose of a Rights Issue of Equity Shares. Transactions in the equity shares of the company will be conducted on an ex-rights basis effective April 28, 2026 under the Rolling Settlement Segment.

Key Points

• Record Date: April 28, 2026
• Rights Ratio: 5 (five) equity shares for every 7 (seven) equity shares held
• Face Value: Rs. 10 per share
• Issue Price: Rs. 15 per share (Rs. 10 face value + Rs. 5 premium)
• Ex-Rights Date: April 28, 2026 (Settlement No. DR-619/2026-2027)
• Payment Schedule: Rs. 3.75 per share payable on application; Rs. 11.25 per share payable on one or more subsequent calls

Regulatory Changes

No new regulatory changes introduced. This is a standard corporate action notification pursuant to BSE listing compliance requirements for rights issues.

Compliance Requirements

• Trading members must note the ex-rights effective date and ensure all transactions in Indrayani Biotech Ltd equity shares are conducted on an ex-rights basis from April 28, 2026 onwards.
• Existing shareholders must be informed that to be eligible for the rights entitlement, shares must be held as of the record date of April 28, 2026.

Important Dates

Impact Assessment

This rights issue is specific to existing shareholders of Indrayani Biotech Ltd (Scrip Code: 526445). Eligible shareholders as of the record date (April 28, 2026) will have the right to subscribe to 5 new equity shares for every 7 shares held at a price of Rs. 15 per share. The staggered payment structure (Rs. 3.75 on application and Rs. 11.25 on calls) reduces the immediate capital outlay for subscribers. Trading members and investors holding or transacting in this scrip should factor in the ex-rights adjustment when evaluating share price from April 28, 2026.